Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DYRK1A enhances antitumor immunity in type 1 conventional dendritic cells via mTORC1 activation [tumor-infiltrating type 1 conventional dendritic cells]

ABSTRACT: Type 1 conventional dendritic cells (cDC1s) play an integral role in mediating immune responses and maintaining homeostasis, yet the molecular mechanisms underlying their functions remain poorly understood. In this study, we identified dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) as a key kinase that responded to TLR and growth factor stimulation and acted as an essential regulator of cDC1 function. Genetic ablation of Dyrk1a specifically in cDC1s impaired antitumor immunity and accelerated tumor progression in murine models. Mechanistically, DYRK1A mediated the phosphorylation of the mTORC1 inhibitor TSC2 at serine 540, triggering the degradation of TSC2 and promoting the mTORC1 signaling in cDC1s. Notably, Tsc2 deletion in Dyrk1a-deficient cDC1s remarkably restored their antitumor immune functions. Furthermore, DYRK1A-mediated mTORC1 signaling in cDC1s positively correlated with effector T-cell responses across multiple human cancers. Our findings highlight a critical role for the DYRK1A-TSC2-mTORC1 signaling pathway in regulating cDC1 functions in antitumor immunity, offering potential strategies to improve cancer immunotherapy.

ORGANISM(S): Mus musculus

PROVIDER: GSE327455 | GEO | 2026/04/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

DYRK1A enhances antitumor immunity in type 1 conventional dendritic cells via mTORC1 activation

Project description:Type 1 conventional dendritic cells (cDC1s) play an integral role in mediating immune responses and maintaining homeostasis, yet the molecular mechanisms underlying their functions remain poorly understood. In this study, we identify dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) as a key kinase that responds to TLR and growth factor stimulation, acting as an essential regulator of cDC1 function. Genetic ablation of Dyrk1a specifically in cDC1s impairs antitumor immunity and accelerates tumor progression in murine models. Mechanistically, DYRK1A mediates the phosphorylation of the mTORC1 inhibitor TSC2 at serine 540, triggering the degradation of TSC2 and promoting the mTORC1 signaling in cDC1s. Notably, Tsc2 deletion in Dyrk1a-deficient cDC1s remarkably restores their antitumor immune functions. Furthermore, DYRK1A-mediated mTORC1 signaling in cDC1s positively correlates with effector T-cell responses across multiple human cancers. Our findings highlight a critical role for the DYRK1A-TSC2-mTORC1 signaling pathway in regulating cDC1 functions in antitumor immunity, offering potential strategies to improve cancer immunotherapy.

2026-04-01 | GSE281370 | GEO

Data of DYRK1A in 293T and perform IP-MS assay

Project description:Dendritic cells (DCs) play an integral role in mediating immune responses and homeostasis, but the molecular mechanism underlying the functions of DCs remains elusive. Here, we identified dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) as a kinase that responds to TLR and growth factor stimulation and acts as an important regulator of DC function. DC-specific DYRK1A deletion blunted antitumor immune responses, rendering mice sensitive to tumor progression. Mechanistically, DYRK1A mediates the phosphorylation of the mTORC1 inhibitor TSC2 at S540 site, thereby facilitating the degradation of TSC complex and promoting the mTORC1 signaling in DCs. Deletion of TSC2 in DCs can restore the defected immune function of DYRK1A-deficient DCs. Importantly, DYRK1A-mediated mTORC1 signaling in DCs positively correlated with the better survival probabilities of melanoma and bladder cancer patients. Thus, our data suggest a pivotal role for the DYRK1A signaling axis in regulating DC functions in antitumor immunity and can be harnessed to improve cancer immunotherapies.

2024-11-12 | PXD057775 |

Harnessing Notch Signaling to Enhance the Generation and Functionality of Human Conventional Type I Dendritic Cells for Cancer Immunotherapy Applications

Project description:Conventional dendritic cell type I (cDC1) are essential for an effective antitumor immune response, and their presence in the tumor microenvironment is positively correlated with clinical benefits. The extremely low frequency of these cell subsets in peripheral blood limits their application as a cellular vaccine for cancer immunotherapy. Developing a robust in vitro culture system for their large-scale generation from hematopoietic stem cells (HSCs) is a potential approach for generating cDC1-based cellular vaccines. We have developed a novel culture system by exploiting the Notch signaling requirement for cDC1 differentiation from HSCs and successfully generated billions of cDC1s from every million input CD34+ cells. We compared the gene expression profiles of cDC1s generated under feeder-free conditions or on feeders with or without Notch ligands using bulk RNA sequencing. Our results confirm that the in vitro-generated cDC1s are bona fide cDC1s and closely resemble naturally circulating cDC1s in vivo. The cDC1 generation system represents a significant opportunity to develop novel cellular vaccines for cancer immunotherapy, leveraging cross-presenting DC subsets.

2025-06-17 | GSE273410 | GEO

STAT3 Inhibits Autocrine Interferon Signaling in Type I Conventional Dendritic Cells

Project description:Type I conventional dendritic cells (cDC1s) are an essential antigen-presenting population, required for generating adaptive immunity against intracellular pathogens and tumors. While the transcriptional control of cDC1 development is well understood, the mechanisms by which extracellular stimuli affect cDC1 function remain unclear. Recently, we demonstrated that the cytokine IL-10 inhibits cDC1 maturation induced upon polyinosinic-polycytidylic acid (poly I:C) exposure via a STAT3-dependent mechanism. Furthermore, utilizing a tumor vaccine strategy, we found STAT3 restrains cDC1-mediated anti-tumor immunity. To understand the pathways by which IL-10 and STAT3 regulate cDC1s, we evaluated transcriptional responses by RNA-sequencing. Bioinformatic analyses indicated that many inflammatory pathways were enriched in cDC1s following poly I:C treatment, while interferon (IFN) signaling was uniquely inhibited by STAT3 upon concomitant exposure to IL-10. We found that poly I:C stimulated production of IFN-b and IFN-g from cDC1s. Concurrent exposure to IL-10 suppressed IFN-b and IFN-g secretion as well as accrual of phosphorylated STAT1 and expression of the IFN-response gene Cxcl10 in cDC1s. By contrast, Stat3-deficient cDC1s were refractory to IL-10, indicating STAT3 controls poly I:C-mediated IFN production and IFN transcriptional responses in cDC1s. Moreover, we found that maturation of cDC1s in response to poly I:C is dependent on the type I IFN receptor. Taken together, our data indicate STAT3 is essential for restraining autocrine type I IFN signaling in cDC1s elicited by poly I:C stimulation.

2022-07-26 | GSE188995 | GEO

Activation of T-regulatory cells during allograft tolerance-induction requires mitochondrial-induced TGFB1 in type 1 conventional dendritic cells

Project description:The role of type 1 conventional dendritic cells (cDC1) in tolerance-induction to solid organ allografts is unknown and important for strategies that seek to prolong allograft viability. Utilizing a murine model deficient in cDC1s, we report cDC1s to be required for donor antigen and costimulation blockade (DST + CoB) tolerance-induction and survival of cardiac allografts. Single-cell RNA sequencing and metabolic analysis revealed upregulation of cDC1 mitochondrial metabolic signatures after in vivo exposure to DST + CoB. Genetic inactivation of cDC1 mitochondrial metabolism reduced both expression of cDC1 TGF-β1 and induction of antigen specific CD4+CD25+FoxP3+ T cells.

2025-03-23 | GSE251761 | GEO

DYRK1A enhances antitumor immunity in type 1 conventional dendritic cells via mTORC1 activation

Project description:DYRK1A enhances antitumor immunity in type 1 conventional dendritic cells via mTORC1 activation

| PRJNA1183738 | ENA

RNAseq of conventional dendritic cells generated from mouse bone marrow cultures under different conditions

Project description:Type 1 conventional dendritic cells (cDC1s) are infrequent immune cells with an essential role in orchestrating immune responses to malignancies or infections. Despite their significance in regulating adaptive immunity, the absence of efficient manufacturing techniques to produce adequate yields of cDC1s has hindered their application in therapeutic settings. Here, we find that Interleukin-4 (IL-4) enhances the yield of cDC1 cells produced from Flt3 ligand (Flt3L) cultures of hematopoietic progenitors from either mice or humans, while inhibiting the generation of plasmacytoid DCs. IL-4 acted predominantly on DC progenitors and its activity relied on the cell intrinsic expression of IL4-RA or STAT6. Both in vitro and in vivo, cDC1s that had been stimulated by IL-4 were effective in activating and promoting the expansion of cytotoxic CD8 T cells. Gene expression analysis pointed to a critical role for IL-4 in promoting cDC1 proliferation in vitro. Overall, our research reveals an unanticipated role for IL-4 in fostering the development and manufacture of bona-fide cDC1s, making it easier to employ them for further mechanistic studies, and opening the door to leveraging their potential use in human diseases.

2025-11-14 | GSE309926 | GEO

Phagocytosis of necroptotic cells optimizes type 1 conventional dendritic cells for induction of a cytotoxic T-cell response

Project description:Whether a T-cell response to dead cells arises depends on whether they harbor recognizable antigens, but also how dead cell debris impacts conventional dendritic cells (cDCs). In all tissues, cell debris is continuously phagocytosed by cDCs that can migrate to lymph nodes (LNs) and initiate T-cell responses, depending on their maturation state. The cDC1 lineage excels at antigen cross-presentation, which is required for induction of the cytotoxic CD8+ T-lymphocyte (CTL) response. At steady state, cDC1s undergo homeostatic maturation, which leads to T-cell non-responsiveness. This cDC1 state has recently been defined by ex vivo transcriptomics as resulting from phagocytosis of apoptotic cell debris. Necroptotic (tumor) cell death has been described as more immunogenic than apoptotic cell death, but its impact on cDC maturation has not been defined. In this study, we use an in vitro model to compare side-by-side the impact of well-defined apoptotic versus necroptotic tumor cell debris on the CTL response induced by cDCs, as well as on phenotype and function of both cDC1s and cDC2s. We confirm that cDC2s are less efficient than cDC1s in dead cell phagocytosis and find that they minimally respond to it in terms of gene expression. Apoptotic cell debris is more efficiently phagocytosed by cDC1s than necroptotic cell debris and induces a cDC1 cell state in vitro that has an evident transcriptomic relationship to the homeostatic maturation state defined ex vivo, thus validating our approach. We identify necroptosis as more potent than apoptosis in inducing a CTL response and attribute this to the ability of necroptotic cell debris to induce a specific, transcriptomically defined maturation state in cDC1s, characterized by cytokine and phosphoinositide signaling, cytoskeletal and metabolic activity and functional differentiation. We suggest that this cDC1 signature may be used to diagnose immunogenicity of necroptosis ex vivo.

2025-12-30 | GSE314783 | GEO

Vacuolar protein sorting 33B deficiency effect on conventional dendritic cell type 1 subpopulation

Project description:Analysis of FACS-sorted conventional dendritic cell type 1 (cDC1) subpopulation in mediastinal lymph nodes (mLNs) from mice with vacuolar protein sorting 33B (Vps33B) specific deletion in DCs in response to house dust mite (HDM). Our results provide insight into the role of Vps33B in regulating the function of cDC1s upon HDM stimulation.

2021-09-23 | GSE184505 | GEO

Cohesin-mediated chromatin remodeling controls the differentiation and function of conventional dendritic cells (Hi-C of HoxB8-FL differentiation)

Project description:The cohesin protein complex extrudes chromatin between CTCF binding sites and organizes it into topologically associated domains (TADs), yet the biological implications of this regulatory mechanism are poorly understood. We show that the cohesin subunit Smc3 is required for the postmitotic differentiation and function of antigen-presenting dendritic cells (DCs). In particular, Smc3 deletion impaired antigen cross-presentation and IL-12 secretion by type 1 conventional DCs (cDC1s), thereby crippling antimicrobial and antitumor immune responses. The chromatin profile of DCs was shaped by the interplay of cohesin and the cDC1-specifying transcription factor IRF8. Conversely, optimal expression of IRF8 itself required CTCF/cohesin-binding elements demarcating the Irf8 gene. Cohesin-mediated chromatin remodeling facilitated chromatin priming at activation-inducible genes; accordingly, deletion of CTCF/cohesin-binding sites flanking the Il12b gene reduced basal and activation-induced IL-12 production by cDC1s. Our data reveal an essential role for cohesin-mediated chromatin regulation in the differentiation and function of a key immune cell type.

2026-01-13 | GSE277284 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data